908 DEVICES INC
908 Devices Inc (ticker: MASS) develops compact analytical instruments used to detect and characterise chemicals and biomolecules across life sciences, pharmaceutical development, forensics and environmental testing. The company is small‑cap and focused on commercialising mass‑spectrometry and related platforms that aim to speed up analyses and reduce lab footprint. Investors should know this is a growth‑oriented business with a modest market capitalisation and a history of investment in product development; profitability and cash flow can be uneven as the company scales. Key considerations include technology adoption, recurring consumables or service revenue, competition from established instrument makers and sensitivity to research spending. Shares can be volatile; diversification, a long time horizon and understanding of execution risk are important. This is general educational information, not personalised investment advice—values can rise or fall and past performance is not a reliable guide to future returns.
Stock Performance Snapshot
Analyst Rating
Analysts strongly recommend buying 908 Devices Inc. as its stock is expected to rise significantly.
Financial Health
908 Devices is showing strong revenue and profitability, indicating solid financial performance and growth potential.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Discover More Opportunities
Abbott
Abbott Laboratories is a global healthcare company that develops and markets a broad range of health care products, including medical devices, diagnostics, nutritionals, and branded generic pharmaceuticals.
AGILENT TECHNOLOGIES INC
Agilent Technologies, Inc. specializes in life sciences, diagnostics and applied markets, providing application-focused solutions that include instruments, software, services and consumables for the entire laboratory workflow. Its segments include Life Sciences and Diagnostics Markets, Agilent CrossLab and Applied Markets. The Life Sciences and Diagnostics Markets segment provides contract development and manufacturing services for pharmaceutical customers as well as solutions that include reagents, instruments, software and consumables which enable customers in the clinical and life sciences research areas to interrogate samples at the cellular and molecular level. The Agilent CrossLab segment spans the entire lab with its services and consumables portfolio in addition to software and laboratory automation solutions, which are designed to improve customer outcomes and represent a range of offerings designed to serve customer needs across end-markets and applications.
ALIGN TECHNOLOGY INC
Align Technology is a medical device company that designs, manufactures and markets a range of dental and orthodontic products.
Baskets Featuring MASS
Wearable Tech IP Wars: What Investors Should Know
Masimo's lawsuit against U.S. Customs, following a reversal of an import ban on Apple Watches, highlights the fierce competition over intellectual property in wearable health. This theme focuses on the medical technology companies and competitors poised to benefit from the ongoing patent battles in the lucrative health-monitoring device market.
Published: August 21, 2025
Explore BasketPharma's American Reshoring Wave
AstraZeneca is investing $50 billion to expand its U.S. manufacturing, partly in response to trade tariffs. This move could spark a wave of similar onshoring efforts, creating opportunities for companies that build, equip, and supply the growing domestic biopharmaceutical industry.
Published: July 23, 2025
Explore BasketWhy You’ll Want to Watch This Stock
Growth through innovation
New compact mass‑spec and microfluidic platforms could open markets beyond traditional labs, though commercial adoption and execution risk remain.
Product‑led revenue
High‑value instruments paired with consumables and service can create recurring income, but scaling sales and support is resource‑intensive.
Diverse end markets
Applications span pharma, forensics and environment, offering diversification; demand can vary with research budgets and regulatory cycles.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.